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The incidence of hepatocellular carcinoma (HCC) keeps rising year by year, and became the second leading cause 
of cancer-related death. Some studies have found that liraglutide, a GLP-1 analog, may decrease the tumor cells 
proliferation. Due to this, the aim of this work is to investigate the antiproliferative potential of exenatide, another 
GLP-1 analog. Cell proliferation was assessed by direct count with Trypan blue dye exclusion. Flow cytometry 
was used to determinate autophagy and nuclear staining. Morphometric analysis was used to verify senescence 
and apoptosis. The mechanism that induced cell growth inhibition was analyzed by Western Blot. Treatment with 
exenatide significantly decreases cell proliferation and increases autophagy, both in relation to control and lirag-
lutide. In addition, mTOR inhibition was greater in cells treated with exenatide. In relation to chronic treatment, 
exenatide does not allow cellular regrowth by preventing some resistance mechanism that the cells can acquire. 
These results suggest that exenatide has a potent anti-proliferative activity via mTOR modulation and, among the 
GLP-1 analogs tested, could be in the future an alternative for HCC treatment. 
 





Hepatocellular cancer is one of the most 
incidental and lethal types of solid tumor in 
the world and the third leading cause of can-
cer-related death (Waller et al., 2015; Ge and 
Huang, 2015). Several factors may contribute 
to the development of HCC, although hepati-
tis B and C are responsible for about 80 % of 
cases (Davis et al., 2008). 
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Without presenting symptomatology in 
the initial phase, most HCCs are already at an 
advanced stage with no opportunity of radical 
operations upon diagnosis and, with cancer 
progression and aggravation of liver dysfunc-
tions, systemic drug treatment becomes inef-
ficient resulting in a worse prognosis for HCC 
(Ge and Huang, 2015). In fact, standard sys-
temic chemotherapy is typically not effective 
for HCC treatment, and until now sorafenib 
seems to be the only available treatment for 
advanced stages (Le Grazie et al., 2017), 
which makes the search for new chemothera-
peutics increasingly important and necessary. 
Glucagon-like peptide-1 (GLP-1), an in-
testinal incretin produced in L-cells and re-
lease in response to meal intake, works by 
promoting the secretion of insulin and de-
creasing plasma glucose. GLP-1 analogs act 
as anti-glycemic hormone, inducing the insu-
lin release from pancreatic β cells. Studies 
have shown its beneficial effects in some dis-
eases, including decreased appetite and gas-
tric emptying, immune regulation, and neu-
ronal protection (Abu-Hamdah et al., 2009; 
Chai et al., 2014; Seufert and Gallwitz, 2014; 
Ussher and Drucker, 2014).  
Exendin-4 is a peptide with 39 amino ac-
ids found in the saliva of the lizard Gila mon-
ster (Eng et al., 1992). It has about 50 % ho-
mology to human GLP-1 and a half-life 
greater than observed for GLP-1 (>10 min) 
(Nielsen et al., 2004). The main difference is 
the presence of glycine in the second amino 
acid of exanatide-4, which is resistant to di-
peptidyl peptidase-4 (DPP-4) cleavage, re-
sulting in a half-life of 30 minutes in humans. 
Exenatide is a synthetic form of exendin-4 
and was the first FDA-approved GLP-1 drug 
in 2005. Evidence has shown the potential 
benefits of exendin-4 in modulating lipid me-
tabolism in a murine model of hepatic steato-
sis and in human hepatocyte (Yoo et al., 2018; 
Gupta et al., 2010). Moreover, one study 
demonstrated that GLP-1 based agents, lirag-
lutide and exendin-4, could reduce steatosis 
by enhancing autophagy (Sharma et al., 
2011). 
Thus, considering that we have previously 
shown that liraglutide, a GLP-1 analog, pre-
sents chemotherapeutic effects for cancer by 
inducing autophagy and senescence in hepa-
tocarcinoma cells (Krause et al., 2017), the 
aim of this study was to compare the antipro-
liferative effects of exenatide and liraglutide. 
 
MATERIALS AND METHODS 
Cells and treatment 
Human hepatocellular carcinoma HepG2 
cell line was acquired from the cell bank of 
Federal University of Rio de Janeiro (Rio de 
Janeiro, Brazil). Cells were grown in Dul-
becco’s Modified Eagle medium (DMEM; 
Gibco, USA) supplemented with 10 % fetal 
bovine serum (FBS; Gibco, USA) FBS, 1 % 
penicillin (100 units/mL) and streptomycin 
(100 µg/mL) (Invitrogen, USA), 2 g/L 
HEPES buffer and 3,7 g/L NaHCO3 in humid-
ified atmosphere of 5 % CO2 at 37 °C. 
Exenatide (Byetta, Baxter Pharmaceutical 
Solutions, USA) and liraglutide (Victoza, 
Novo Nordisk A/S, Denmark) were used at a 
final concentration of 15 µM (Krause et al., 
2017). HepG2 cells were incubated and the 
analyses were performed 48 h after treatment. 
All experiments were performed five times. 
 
Cell proliferation 
HepG2 cells were seeded at a density of 
2.5×104 cells/well into 96-well plates and 
treated with exenatide or liraglutide (15 µM) 
for 48 h. The cell number was counted in a 
Neubauer chamber by Trypan blue dye exclu-
sion. The cellular viability was evaluated by 
mixing 25 μL of cell suspension and 25 μL of 
0.4 % Trypan blue stain solution (Sigma-Al-
drich, USA). Blue cells were counted as dead 
cells. Three replicate wells were used at each 
concentration tested, including control. 
 
Cytotoxicity 
The analysis of the enzyme lactate dehy-
drogenase (LDH) was used to assess treat-
ment cytotoxicity in HepG2 cells, since the 
LDH released from the cytoplasm into the cell 
culture medium is an evidence of cellular 
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damage (membrane disruption). Lactate de-
hydrogenase assay (Labtest Diagnóstica, Bra-
zil) was performed in both supernatants and 
cell lysate following manufacturer’s instruc-
tions. The LDH concentration was determi-
nated spectrophotometrically at 492 nm. For 
the control of cell lysis, DMEM with 5 % 
Tween solution was used. For the evaluation 
of the enzymatic content, the sum of the LDH 
amount in the supernatant and the cell lysate 
was considered 100 %. 
 
Nuclear morphometric analysis (NMA) 
To evaluate apoptosis and senescence, the 
size and irregularity of the cellular nuclei 
were analyzed. Cells were seeded in 24-well 
plates (10×103 cells/well), treated with 15 µM 
of exenatide and 20 µM of cisplatin. After 48 
h of incubation, the cells were fixed with 4 % 
paraformaldehyde for 2 h. Next, fixed cells 
were permeabilized with 0.3 % Triton X-100 
in phosphate buffered saline (PBS) for 30 min 
and stained with 300 nM of 4´,6-diamidino-2-
phenylindole (DAPI) for 2 min in a dark con-
dition at room temperature. Cells were photo-
graphed with a fluorescence microscope 
(IX71, Olympus) and the nuclear morphome-
try was evaluated using the Image Pro Plus 
6.0 software (IPP 6 – Media Cybernetics, 
USA). The nuclear morphological changes 
were classified as normal, small and regular, 
large and regular, or irregular. 
 
Autophagy analysis 
The formation of acidic vesicular orga-
nelles (AVO's) is a morphological character-
istic of autophagy. We quantified AVO’s by 
Acridine Orange staining, in which the acid 
compartments display orange fluorescence, 
an autophagic marker. Briefly, the cells were 
seeded into 96-well plates at a density of 
2.5×104 cells per well and treated with 15 µM 
of exenatide and 200 nM of rapamycin for 
48 h. The Acridine Orange marked cells were 
evaluated with FACSCanto II flow cytometer 
(BD Bioscience, USA) and analyzed using 
FlowJo 10.0.8 software (Tree Star Inc., USA). 
mTOR activation 
In order to evaluate the exenatide activity 
on mammalian target of rapamycin (mTOR), 
cells were treated with insulin 200 nM (posi-
tive control for mTOR activation), rapamycin 
200 nM (positive control for mTOR inhibi-
tion) and GLP-1 analogs. In order to deter-
mine the cell number, cells were counted with 
a Neubauer chamber. The cellular viability 
was evaluated by mixing 25 μL of cell sus-
pension and 25 μL of 0.4 % Trypan blue stain 
solution (Sigma-Aldrich, USA). Blue cells 
were counted as dead cells. 
 
mTOR expression 
For the Western Blot analysis, cells were 
rinsed twice with PBS and lysed with Triton 
lysis buffer with protease inhibitor for protein 
extraction. Aliquots from each sample con-
taining equal amounts of protein were run on 
a SDS page gel, and transferred to a nitrocel-
lulose membrane. Next, membranes were 
blocked with Tris buffered saline containing 
0.05 % Tween-20 and 5 % non-fat dry milk 
and incubated overnight at 4 ºC with primary 
antibodies against mTOR (1:500 dilution; 
Cell Signaling Technology, USA) and 
GAPDH (1:1000 dilution; Thermo Fisher Sci-
entific, USA). Then, the membranes were in-
cubated for 1 h with the appropriate horserad-
ish peroxidase-conjugated secondary anti-
body (Goat anti-Rabbit, dilution 1:2000, Cell 
Signaling Technology, USA; and Rabbit anti-
Mouse, dilution 1:2000, Thermo Fisher Sci-
entific, USA) at room temperature. Values of 
proteins were normalized to GAPDH. 
 
Treatment resistance analysis 
Cumulative population doubling (CPD) 
assay was used to evaluate the proliferation 
rate and the regrowth of HepG2 cells after ex-
enatide (15 µM), liraglutide (15 µM) or cis-
platin (20 µM) treatment. The cells were 
seeded (5 x 105) in a 6-well plate and har-
vested for 48 h. After, cells were seeded with 
a cell density of 12 x 104, 9 x 104, 6 x 104 and 
3 x 104 cells per well in 24-well plates and in-
cubated for 24 h. The cells were retreated as 
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previously described, followed by cell count-
ing. The number of viable cells was deter-
mined by Trypan blue stain solution (Sigma-
Aldrich, USA), using a hemocytometer under 
a light microscope (Nikon Optiphot, Japan). 
The cells were counted in the second, third, 
fourth and fifth day after seeding. Population 
doubling (PD) of each interval was deter-
mined according to the formula PD = [log 
N(t) - log N(to)]/log 2, where N(t) is the num-
ber of cells at the time count, and N(to) is the 
number of cells seeded. The sum of PDs was 
then plotted against time of culture. 
 
Statistical analysis 
The normality of the data was tested using 
the Shapiro-Wilk test. Data were analyzed us-
ing a one way ANOVA followed by Tukey 
multiple comparison test using Statistical 
Package for the Social Sciences Version 13.0 
(SPSS, Inc., USA). A value of p<0.05 was 
considered as statistically significant. 
 
RESULTS 
First, we investigated which of the treat-
ments showed better antiproliferative effect. 
We observed that exenatide treatment was 
able to decrease viable cells by around 45 %, 
whereas liraglutide demonstrated a 23 % of 
proliferation decrease (Figure 1A). In order to 
assess whether this growth decrease was 
caused by cytotoxicity, the LDH release was 
evaluated. There was no significant difference 
between treated and control groups, demon-
strating that viability decrease was not due to 
necrosis, suggesting that another mechanism 
may be involved in this response (Figure 1B).  
Senescence and apoptosis are two know 
mechanisms of anticancer drugs. For this rea-
son, they were evaluated as a possible cause 
of the decreased cell proliferation observed. 
In the NMA test, it is possible to evaluate nu-
clear morphometric parameters that enable 
the identification of these cellular processes. 
In Figure 1C, red arrows indicate senescent 
nuclei and yellow arrows apoptotic nuclei. 
Exenatide treatment did not demonstrate an 
increase of senescent or apoptotic cells, un-
like liraglutide treatment, which demon-
strated senescence induction, indicating that 
the drugs may act on different routes. Cispla-
tin was used as a positive control (Figure 1C 
and 1D).  
Autophagy is another well-known mecha-
nism of cell proliferation decreased in cancer, 
and, for this reason, we investigated if ex-
enatide and liraglutide were able to induce au-
tophagy in HCC cells. Our results demonst-
rate that exenatide treatment significantly in-
creases autophagy, both in comparison to the 
control and in comparison to liraglutide treat-
ment. Rapamycin was used as a positive con-
trol (Figure 1E and 1F).  
Next, we tried to verify if the decrease in 
cell proliferation by exenatide was related to 
the modulation of mTOR signaling. Thus, the 
cells were pre-treated or not with insulin, ra-
pamycin, liraglutide, and exenatide. Our re-
sults showed that exenatide is able to inhibit 
insulin stimulation, as well as rapamycin and 
liraglutide, in a more pronounced way than li-
raglutide, suggesting that one possible mech-
anism of action is through the mTOR pathway 
(Figure 2A). To confirm these findings, we 
have also evaluated the mTOR protein ex-
pression and results have shown a decrease in 
the treated groups, with the exenatide effect 
more potent than liraglutide (Figure 2B). 
Therefore, we decided to investigate the 
effects of long-term response of HepG2 cells 
after the treatment with exenatide and lirag-
lutide, in single or multiple doses. The appli-
cation of a single dose of exenatide did not 
suppress the regrowth of HepG2 cells, as well 
as both single and multiple doses of lirag-
lutide treatment. However, multiple doses 
treatment with exenatide led to a stable arrest 
of the cell growth, indicating that exenatide 
may be a better long-term treatment for this 
tumor cell type (Figure 3A and 3B). 
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Figure 1: Effect of exenatide and liraglutide on cell proliferation, cytotoxicity, nuclear morphometry and 
autophagy of HepG2 cells. (A) HepG2 cells were treated with liraglutide (15 µM) or exenatide (15 µM) 
for 48 h. Cell viability was assessed by direct cell counting. Results are expressed as percentage of 
cells in relation to control. (B) Percentage of LDH release by HepG2 cells after treatment with liraglutide 
(15 μM) or exenatide (15 μM). Results are expressed as percentage of LDH release into the superna-
tant. (C) Representative images of nuclei from cell control and cells exposed to liraglutide (15 μM), 
exenatide (15 μM), and cisplatin (20 μM) for positive control. Red arrows indicate senescent nuclei and 
yellow arrows apoptotic nuclei. (D) DAPI-stained nuclei were analyzed for size and irregularity, and the 
percentage of senescent cells is show. (E) Representative flow cytometry plots in autophagy FITC (x 
axis) / PerCP Cy5 (y axis). (F) Cells were exposed to liraglutide (15 μM), exenatide (15 μM) and, ra-
pamycin (200 nM). Results are expressed as percentage of autophagic cells. Data represent the mean 
± SD (n = 3-5) (*p < 0.05, **p < 0.01, ***p < 0.001 vs control) (&&& p < 0.001 vs liraglutide). 
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Figure 2: Effect of GLP-1 analogs on mTOR activation and protein expression. (A) HepG2 cells 
were treated with insulin (200 nM), rapamycin (200 nM), liraglutide (15 μM) or exenatide (15 μM) for 
48 h. Cell viability was assessed by direct cell counting. Results are expressed as percentage of cells 
in relation to control. Data represent the mean ± SD (n =5) (*p < 0.05 vs control, **p < 0.01 vs control, 
***p < 0.001 vs control) (& p < 0.05 vs liraglutide). (B) mTOR expression on HepG2 cells after treatment 
for 48h with liraglutide (15 μM) or exenatide (15 μM). Results are expressed as normalized pro-




Figure 3: Exenatide reduces 
tumor cell regrowth. (A) 
Protocol of treatment. (B) 
Cells were exposed to lirag-
lutide (15 μM), exenatide (15 
μM) and cisplatin (20 μM pos-
itive control). Data represent 
the mean ± SD (*p < 0.05 vs 
control, ***p < 0.001 vs con-
trol) (&& p < 0.01, &&& p < 0.001 
vs liraglutide). RT represents 
retreatment. 
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GLP-1 exerts its role by binding to its spe-
cific receptor (GLP-1R) on human hepato-
cytes (Yoo et al., 2018). Despite the contro-
versy about the presence of these receptors in 
the liver, a recent study in human hepatoma 
cell lines revealed that exenatide has a dose-
dependent effect in the increase of GLP-1R 
expression (Lee et al., 2012). As an analog of 
GLP-1, which was first authorized to treat 
type 2 diabetes mellitus, exenatide can bind to 
the GLP-1R of pancreatic β-cells promoting 
the secretion of insulin. A clinical study with 
exenatide in type 2 diabetes showed a de-
creased hepatic fat accumulation, insulin re-
sistance, and risk of cardiovascular diseases 
(Tushuizen et al., 2006). 
Several studies have shown that GLP-1 
analogs may have anticancer potential. Chen 
et al. demonstrated an enhanced effect of 
chemotherapy in a mouse model of bile duct 
carcinoma treated with exendin-4 (Chen et al., 
2013). Moreover, experimental studies have 
shown that exendin-4 could inhibit and atten-
uates tumor growth (Honors and Kinzig, 
2014; Nomiyama et al., 2014). Other studies 
revealed that GLP-1 analog liraglutide inhib-
its the growth of pancreatic cancer in animal 
models and hepatocellular carcinoma in 
HepG2 cell line (Zhao et al., 2014; Krause et 
al., 2017). These results corroborate our find-
ings that exenatide decrease HepG2 cells via-
bility after 48 h of treatment. In addition, the 
effect caused by exenatide demonstrates a 
greater potential for treatment than lirag-
lutide, suggesting that exenatide may be con-
sidered as an important adjuvant in the treat-
ment of HCC. Besides that, our results 
showed a low reduction of cell viability with 
a short treatment of 48 h.  
Knowing that liraglutide is capable of in-
ducing senescence in HepG2 cells (Krause et 
al., 2017), we have tested this effect for ex-
enatide. Senescence and apoptosis are two 
mechanisms that may be responsible for the 
proliferation decrease, as the first is character-
ized by an irreversible cell cycle arrest 
(Childs et al., 2014) and the second by a pro-
grammed cell death with nuclear fragmenta-
tion (He et al., 2009). While senescent cells 
adopt an expanded morphology, with flat-
tened cytoplasm and increased granularity, 
the apoptotic cells suffer a high and regular 
condensation of the nucleus causing nuclear 
fragmentation (Saraste, 1999). However, the 
treatment with exenatide did not show any 
morphological changes in the cellular nuclei, 
suggesting that there was no induction of se-
nescence or apoptosis. 
Another physiological cellular process in-
volved in this mechanism is autophagy, which 
is one route of lysosome degradation that reg-
ulates cellular lipid metabolism and controls 
the innate immune activation, improving the 
state of insulin resistance and cancer (Dikic 
and Elazar, 2018). Several works reported the 
beneficial effects of autophagy in carcinogen-
esis and studies of GLP-1 analogs have shown 
its ability to increase autophagy (He et al., 
2016; Li et al., 2017). Here, we demonstrated, 
corroborating other studies, that exenatide is 
capable of inducing autophagy at a higher 
level than liraglutide, showing a superior po-
tential and possibly justifying the decrease of 
cellular proliferation. To confirm the hypoth-
esis that exenatide would be more efficient, 
we have also assessed how it would act on 
mTOR activation and inhibition.  
Autophagy is regulated by a complex sig-
naling network and mTOR pathway is the 
main regulatory mechanism for its suppres-
sion (Paquette et al., 2018). We observed that 
exenatide was able to inhibit insulin stimula-
tory effect in a more significant way than li-
raglutide, proving to have a greater effect. In 
addition, we demonstrated that liraglutide is 
able to inhibit mTOR protein expression in 
HepG2 cells, but exenatide causes a greater 
inhibition, justifying its greater induction of 
autophagy.  
Exenatide also showed antiproliferative 
effects in the treatment resistance analysis. 
The long-term evaluation and retreatment al-
lowed the in vitro assay to be more compara-
ble to clinical treatments, in which patients 
are submitted to many chemotherapeutic 
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doses. This assay is clinically relevant, con-
sidering that chronic in vitro results are 
strongly associated with in vivo findings. (Au-
gustine et al., 2009). In our results, exenatide 
showed a greater potential to inhibit prolifer-
ation than liraglutide was able to maintain this 
effect over time. 
We demonstrated for the first time that ex-
enatide treatment does not allow the cells to 
grow again over time, one of the main prob-
lems experienced with the current chemother-
apeutics, as shown for cisplatin. This re-
sistance acquired by the cells makes the 
chemotherapy ineffective (Rebucci and 
Michiels, 2013). Still, with exenatide, this re-
sistance mechanism does not appear to occur, 
suggesting that this treatment may be an im-
portant finding in the search for new chemo-
therapeutics.  
Among the GLP-1 analogs tested, ex-
enatide may be a better choice, as compared 
to liraglutide, for the HCC treatment. Further-
more, our results suggest that exenatide was 
able to attenuate the growth of HepG2 cells 
and the mTOR pathway may be the target of 
the underlying mechanism. However, further 
studies, both in vivo and clinical trials, should 
be employed in the search for the mechanisms 
in which exenatide is involved in the HCC, 
making this peptide a promising treatment for 
a disease of high incidence and mortality. 
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